Список проголосовавших за комментарий " Gapping up/down: WAC +9%, YY +5%, DSW +3% and PUK +2% after earnings; MGI +23% after M&A news; RYI -8% and HDS -2% after earnings, VRX -11% after reports Ackman sold stake<p><strong>Gapping up<br/> In reaction to strong earnings/guidance</strong>:</p><ul><li><strong>WAC</strong> +9.3%, <strong>EARS</strong> +7.1%, <strong>YY</strong> +4.5%, <strong>ALBO</strong> +4%, <strong>EGY</strong> +3.8%, <strong>DSW</strong> +3.3%, <strong>REN</strong> +3%, <strong>SCYX</strong> +2.3%</li><li><strong>PUK</strong> +2.2%, <strong>ATRS</strong> +1.2%, <strong>GRBK</strong> +1.2%, <strong>ENOC</strong> +0.9%, <strong>VALU</strong> +0.8%, <strong>TRHC</strong> +0.6%</li></ul><p><strong>M&A news</strong>:</p><ul><li><strong>MGI</strong> +23.5% (Euronet Worldwide (EEFT) has made competing proposal to acquire MGI for $15.20/share)</li><li><strong>CBR</strong> +10.2% (confirms receipt of non-binding letter of interest from Ameri Holdings to acquire co for $0.75 per share)</li><li><strong>LCUT</strong> +5.8% (receives takeover offer for $20.00 per share from Mill Road Capital)</li></ul><p><strong>Other news</strong>:</p><ul><li><strong>DRWI</strong> +34.8% (Signs new Master Sales and Services Agreement with Ingram Micro Australia)</li><li><strong>TDW</strong> +27.4% (Receives additional limited waiver extensions from its lenders and noteholders)</li><li><strong>ETRM</strong> +21.5% (Announced that its vBloc Neurometabolic Therapy for the treatment of obesity will be featured on the March 14 episode of the Emmy Award-winning syndicated daytime talk show The Doctors)</li><li><strong>SBOT</strong> +17% (Enters into a technology transfer and purchase agreement with Matrivax Inc related to Stellar's proprietary Clostridium difficile technology)</li><li><strong>TNXP</strong> +7.8% (announces that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application covering composition and manufacture of tnx-102 sl)</li><li><strong>RTTR</strong> +4.7% (Discloses holding a a Type C informational meeting with the FDA)</li><li><strong>COKE</strong> +3.5% (To join the S&P SmallCap 600)</li></ul><p><strong>Analyst comments</strong>:</p><ul><li><strong>ARRS</strong> +5.1% (upgraded to Buy from Neutral at Goldman)</li><li><strong>OPK</strong> +1.3% (initiated with a Buy at Guggenheim; tgt $25)</li><li><strong>LADR</strong> +0.9% (upgraded to Outperform from Market Perform at Wells Fargo)</li><li><strong>WMT</strong> +0.6% (added to US 1 List at BofA/Merrill)</li></ul><p><strong>Gapping down<br/> In reaction to disappointing earnings/guidance</strong>:</p><ul><li><strong>CIE</strong> -14.4%, <strong>TLYS</strong> -12.5%, <strong>PN</strong> -12.3%, <strong>AMPH</strong> -10.1%, <strong>RYI</strong> -8.4%, <strong>PETX</strong> -6.5%, <strong>APRI</strong> -6.4%</li><li><strong>GBT</strong> -4.5%, <strong>PPHM</strong> -3.1%, <strong>TPVG</strong> -2%, <strong>COUP</strong> -1.9%, <strong>HDS</strong> -1.7%, <strong>BLCM</strong> -0.6%</li></ul><p><strong>Select EU financial related names showing weakness</strong>:</p><ul><li><strong>RBS</strong> -4.5%, <strong>LYG</strong> -3.5%, <strong>BCS</strong> -2%, <strong>PSO</strong> -1.4%, <strong>DB</strong> -1.6%, <strong>HSBC</strong> -1.4%, <strong>SAN</strong> -0.9%</li></ul><p><strong>Select metals/mining stocks trading lower</strong>:</p><ul><li><strong>MT</strong> -1.6%, <strong>RIO</strong> -1.4%, <strong>VALE</strong> -1.3%, <strong>BHP</strong> -1%, <strong>HMY</strong> -0.9%, <strong>FCX</strong> -0.9%, <strong>AU</strong> -0.8%, <strong>AUY</strong> -0.8%, <strong>GFI</strong> -0.6%</li></ul><p><strong>Select oil/gas related names showing early weakness</strong>:</p><ul><li><strong>WLL</strong> -1.9%, <strong>SWN</strong> -1.7%, <strong>ESV</strong> -1.4%, <strong>MRO</strong> -1.3%, <strong>TOT</strong> -1.2%, <strong>RDS.A</strong> -1.1%, <strong>DVN</strong> -1.1%</li></ul><p><strong>Other news</strong>:</p><ul><li><strong>ANTH</strong> -32.3% (To offer and sell shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering)</li><li><strong>AUPH</strong> -23.3% (Commences common stock offering)</li><li><strong>ADPT</strong> -20.3% (Amends credit agreement, hires chief restructuring officer and financial advisor to advise the Board and management as they explore various strategic alternatives)</li><li><strong>CBIO</strong> -16.4% (Files for $12 mln offering of Class A Units consisting of common stock and warrants and Class B Units consisting of shares of Series A Preferred Stock and warrants)</li><li><strong>VRX</strong> -11% (Ackman's Pershing Square sells its stake)</li><li><strong>KNDI</strong> -10.3% (Determines that some previously issued financial statements should no longer be relied upon)</li><li><strong>LNTH</strong> -9.6% (To sell 3 mln shares of its common stock to be offered by certain of its existing stockholders)</li><li><strong>DOC</strong> -3.8% (prices offering of 15 mln shares of common stock at $18.20 per share)</li><li><strong>CORT</strong> -3.6% (Files for $200 mln mixed securities shelf offering, as well as 349k share offering by selling stockholders)</li></ul><p><strong>Analyst comments</strong>:</p><ul><li><strong>GLW</strong> -1.5% (downgraded to Neutral from Buy at Goldman)</li></ul>"